atomoxetine /kg/day

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Attention Deficit Hyperactivity DisorderSocial Anxiety DisorderVasovagal SyncopeOppositional Defiant Disorder

102 competitors in Attention Deficit Hyperactivity Disorder

#DrugCompanyPhaseTrials

1

atomoxetine /kg/day

Eli Lilly

Approved

122

Circadin

NNeurim Pharmaceuticals Ltd.

Phase 3

23

Catapres

Boehringer Ingelheim

Phase 3

14

Ambien

PPurdue Pharma LP

Phase 3

15

Provigil

NNuvo Research GmbH

Phase 3

16

OROS Oxybutynin

Johnson & Johnson

Phase 3

47

Sunosi

AAxsome Therapeutics, Inc.

Phase 3

18

Ritalin

Pfizer

Phase 3

59

Cymbalta

Alnylam Pharmaceuticals

Phase 2

110

Adderall-XR

NNew River Pharmaceuticals

Phase 3

2Show 26 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Attention Deficit Hyperactivity Disorder12 trials

Comparison of Atomoxetine and Placebo in Children With Attention-Deficit/Hyperactivity Disorder (ADHD) and/or Reading Disorder (RD)

Completed·Eli Lilly·Phase 4·NCT00191906·121 enrolled

Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) With Atomoxetine in Young Adults and Its Effects on Functional Outcomes

Completed·Eli Lilly·Phase 4·NCT00510276·445 enrolled

Comparison of Lisdexamfetamine Dimesylate With Atomoxetine HCl in Attention-Deficit/Hyperactivity Disorder (ADHD) Subjects With an Inadequate Response to Methylphenidate

Completed·Takeda·Phase 3·NCT01106430·267 enrolled

Show 9 more trials

Neuropsychological Functioning in Children With Attention-Deficit/Hyperactivity Disorder.

Completed·Eli Lilly·Phase 4·NCT00216918·40 enrolled

Efficacy and Safety of Extended-release Guanfacine Hydrochloride in Children and Adolescents Aged 6-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)

Completed·Takeda·Phase 3·NCT01244490·338 enrolled

A Long Term Study of a Medication for Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

Completed·Eli Lilly·Phase 3·NCT00700427·2,017 enrolled

A Randomized, Double-Blind Comparison of Placebo and Atomoxetine Hydrochloride Given Once a Day in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

Completed·Eli Lilly·Phase 4·NCT00190775·502 enrolled

Efficacy and Safety of Atomoxetine in Children With Recent Diagnosis of Attention-Deficit/Hyperactivity Disorder (ADHD)

Completed·Eli Lilly·Phase 3·NCT00191945·151 enrolled

Long-Term Study of Atomoxetine in Children With Attention-Deficit/Hyperactivity Disorder (AD/HD)

Completed·Eli Lilly·Phase 3·NCT00191386·228 enrolled

A Study of TAK-503 in Children and Teenagers With Attention Deficit Hyperactivity Disorder (ADHD)

Completed·Takeda·Phase 4·NCT04085172·396 enrolled

A Functional Outcomes Study With Atomoxetine-Hydrochloride and Placebo in Adults With Attention-Deficit/Hyperactivity Disorder

Completed·Eli Lilly·Phase 4·NCT00190931·400 enrolled

Atomoxetine to Treat Korean Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)

Completed·Eli Lilly·Phase 3·NCT00568685·153 enrolled

Children3 trials

Safety Study in Outpatient Japanese Children With ADHD

Completed·Eli Lilly·Phase 2·NCT00485628·37 enrolled

Analog Classroom Study Comparison of ADDERALL XR With STRATTERA in Children Aged 6-12 With ADHD

Completed·Takeda·Phase 4·NCT00506727·215 enrolled

Comparison of Atomoxetine Plus Either Comparator or Placebo in Children With ADHD Who Haven't Responded to Stimulant Therapy

Completed·Eli Lilly·Phase 3·NCT00485550·14 enrolled

Adolescent3 trials

Comparison of Atomoxetine and Placebo in Children and Adolescents With ADHD and ODD

Completed·Eli Lilly·Phase 3·NCT00191698·226 enrolled

Study of Broader Efficacy of Atomoxetine in the Treatment of ADHD in Children/Adolescents

Completed·Eli Lilly·Phase 3·NCT00191659·200 enrolled

Atomoxetine Hydrochloride Versus Placebo in Taiwanese Children and Adolescents With ADHD

Completed·Eli Lilly·Phase 3·NCT00485459·106 enrolled

Attention1 trial

A Study of Atomoxetine for Attention Deficit and Hyperactive/Impulsive Behaviour Problems in Children With ASD

Completed·Eli Lilly·Phase 4·NCT00485849·12 enrolled

Effectiveness1 trial

Effectiveness of ATMX in Treating Adolescents With ADHD and SUD

Completed·MMassachusetts General Hospital·Phase 4·NCT00218322·108 enrolled

12 more indications

Trial1 trial

Parallel Arm Trial of AD109 and AD504 In Patients With OSA

Completed·AApnimed·Phase 2·NCT05071612·294 enrolled

Combination Therapy1 trial

Combination Therapy in Patients With Depression

Completed·Eli Lilly·Phase 4·NCT00485862·214 enrolled

Alzheimer's Disease1 trial

Adding Atomoxetine To Standard Medication Treatment In Patients With Alzheimer's Disease

Completed·Eli Lilly·Phase 2/3·NCT00191009·124 enrolled

Efficacy and Safety1 trial

Efficacy and Safety of Once-Daily Atomoxetine Hydrochloride in Adults With ADHD Over an Extended Period of Time (6 Months)

Completed·Eli Lilly·Phase 4·NCT00190736·440 enrolled

Treatment1 trial

Evaluation of Continuous Symptom Treatment of ADHD

Completed·Eli Lilly·Phase 4·NCT00486122·282 enrolled

Social Anxiety Disorder1 trial

Placebo-Controlled Study of Atomoxetine Hydrochloride in the Treatment of Adults With ADHD and Comorbid Social Anxiety Disorder

Completed·Eli Lilly·Phase 4·NCT00190879·440 enrolled

Safety and Efficacy1 trial

Safety and Efficacy of Switching From a Stimulant Medication to Atomoxetine in Children and Adolescents With ADHD

Completed·Eli Lilly·Phase 4·NCT00485875·62 enrolled

Vasovagal syncope1 trial

Study of Atomoxetine in the Prevention of Vasovagal Syncope

Recruiting·UUniversity of Calgary·Phase 3·NCT05159687·180 enrolled

Pediatric1 trial

Comparison Atomoxetine Hydrochloride and Comparator in Pediatric Outpatients With ADHD

Completed·Eli Lilly·Phase 3·NCT00486083·330 enrolled

Cognitive Function1 trial

ADDERALL XR (Mixed Salts of a Single-entity Amphetamine) and STRATTERA ( Atomoxetine Hydrochloride) Compared to Placebo on Simulated Driving Safety and Performance and Cognitive Functioning in Adults With ADHD

Completed·Takeda·Phase 3·NCT00557960·36 enrolled

Oppositional defiant disorder1 trial

An Italian Study of the Efficacy of Atomoxetine in the Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD) and Comorbid Oppositional Defiant Disorder (ODD).

Completed·Eli Lilly·Phase 3·NCT00192023·139 enrolled

Unspecified2 trials

Atomoxetine PBPK-PD Clinical Study

Completed·—··NCT03154359·51 enrolled

Guiding Dose Increases in Patients Incompletely Responsive to Usual Doses of Atomoxetine

Completed·Eli Lilly·Phase 3·NCT00485407·377 enrolled

Details

Drug Info

Related News